<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199147</url>
  </required_header>
  <id_info>
    <org_study_id>AML-elderly 01/99 Trial</org_study_id>
    <nct_id>NCT00199147</nct_id>
  </id_info>
  <brief_title>Efficacy of G-CSF-Priming in Elderly AML Patients</brief_title>
  <official_title>Treatment of Elderly Patients (&gt;60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      Aim of the study is to compare the efficacy of intensive induction therapy with Cytarabine,
      Idarubicin and Etoposide (IdAV) given in parallel with (G-CSF priming) and followed by G-CSF
      versus the same IdAV chemotherapy only followed by G-CSF (without priming) in elderly
      patients with de novo AML, secondary AML and advanced MDS. Moreover, the ability to mobilize
      sufficient numbers of peripheral blood stem cells (PBSC) for autologous PBSC transplantation
      after consolidation therapy with dose-reduced FLAG-Ida chemotherapy followed by G-CSF will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2000</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-Remission rate after induction therapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Remission duration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Disease free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Toxicity according to WHO</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Death in induction therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Feasibility to mobilize peripheral blood stem cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Feasibility to perform autologous or allogeneic stem cell transplantation in elderly patients</measure>
  </secondary_outcome>
  <enrollment>250</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell apheresis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of de-novo AML, FAB M0, 1, 2, 4-7 or

          -  Diagnosis of secondary AML after previous chemotherapy and/or radiation therapy or
             after preceeding MDS or

          -  Diagnosis of an advanced MDS, i.e. RAEB-t according to the FAB classification or

          -  Extramedullary AML (chloroma, “granulocytic sarcoma”)

          -  Age greater than 60 years (not including 60 years)

          -  ECOG performance status 0, 1, or 2

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with a t(15;17) translocation

          -  Patients with severe cardiac disease (e.g. cardiac failure NYHA III/IV, myocardial
             infarction within the last 6 months; severe ventricular arrythmias (Lown III or IV)

          -  Patients with severe complications of the leukemia such as uncontrolled bleeding,
             pneumonia with hypoxia or shock.

          -  Severe pulmonary disease (diffusion capacity for CO2 of less than 50%)

          -  Significant renal dysfunction (creatinine clearance &lt; 60/min/min)

          -  Bilirubin &gt; 2mg% (&gt;34.2 mmol/l)

          -  Patients with a clinically active second malignancy

          -  Patients with a psychiatric, addictive, or any disorder wich compromises ability to
             give truly informed consent for participating in this study

          -  HIV positivity

          -  Known refractoriness to platelet transfusion, inability to adequately substitute blood
             products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver G Ottmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Medical Department II, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Medical Department II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver G Ottmann, MD</last_name>
      <phone>++49-69-6301-4802</phone>
      <email>ottmann@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Gesine Bug, MD</last_name>
      <phone>++49-69-6301-4802</phone>
      <email>g.bug@em.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Oliver G Ottmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gesine Bug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 25, 2005</last_update_submitted>
  <last_update_submitted_qc>October 25, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

